Progenity Announces Two Poster Presentations at Controlled Release Society 2022

Rhea-AI Summary

Progenity, a biotechnology company (Nasdaq: PROG), announced the acceptance of two abstracts that will present preclinical data on their systemic therapeutics delivery system at the Controlled Release Society (CRS) 2022 Annual Meeting, scheduled for July 11-15, 2022, in Montreal, Canada. The abstracts cover the development and performance assessment of an oral biotherapeutic delivery system. They will be published by CRS before the conference and available on Progenity’s website post-event.

Positive

• Acceptance of two abstracts for presentation at CRS 2022 Annual Meeting, indicating recognition in the field.
• Focus on innovative oral biotherapeutics, potentially expanding market opportunities.

Negative

• None.

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year’s meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022.

Details of the presentations are as follows:

Abstract Title:	Development of ex-vivo and in-vivo models to assess the performance of an oral biotherapeutic delivery system capsule. (3732683)
Presenting Author:	Christopher Wahl, MD, MBA
Session Type:	Poster Session
Session Date:	July 13 & 14
Abstract Title:	Assessing the performance of an oral biotherapeutic delivery system using intra-duodenal endoscopy delivery in Yucatan minipigs (3732923)
Presenting Author:	Christopher Wahl, MD, MBA
Session Type:	Poster Session
Session Date:	July 13 & 14

Abstracts will be published by CRS in advance of the conference. Poster presentations will be made available on the Progenity website following the conference.

About Progenity 
Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics and is developing a suite of investigational ingestible devices designed to provide precise drug delivery solutions and diagnostic sampling. Progenity’s vision is to transform healthcare to become more precise and personal by improving patient outcomes through localized treatment with targeted therapies.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
ir@progenity.com
(917) 741-7792

Media Contact
Kristin Schaeffer
CG Life
media@progenity.com  
(858) 457-2436

FAQ

What abstracts is Progenity presenting at the CRS 2022 Annual Meeting?

Progenity is presenting two abstracts on their systemic therapeutics delivery system, focusing on performance assessment models.

When and where is the CRS 2022 Annual Meeting taking place?

The CRS 2022 Annual Meeting will be held from July 11-15, 2022, in Montreal, Canada.

What is the significance of Progenity's presentations at the CRS 2022?

The presentations highlight advancements in oral biotherapeutics, showcasing Progenity's innovation in drug delivery technologies.

What is the ticker symbol for Progenity?

Progenity is listed on Nasdaq under the ticker symbol PROG.